These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 20222025

  • 1. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
    Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ.
    J Pharm Sci; 2010 Aug; 99(8):3415-29. PubMed ID: 20222025
    [Abstract] [Full Text] [Related]

  • 2. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ.
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [Abstract] [Full Text] [Related]

  • 3. Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dihydrate and D-mannitol carriers.
    Mansour HM, Xu Z, Hickey AJ.
    J Pharm Sci; 2010 Aug; 99(8):3430-41. PubMed ID: 20229601
    [Abstract] [Full Text] [Related]

  • 4. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 5. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM, MacRitchie HB, Marriott C, Martin GP.
    Int J Pharm; 2007 Mar 21; 333(1-2):45-55. PubMed ID: 17064863
    [Abstract] [Full Text] [Related]

  • 6. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D, Martin GP, Marriott C.
    J Pharm Sci; 2009 Feb 21; 98(2):503-15. PubMed ID: 18506819
    [Abstract] [Full Text] [Related]

  • 7. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN, Bierend H, Robins E, Steckel H, Flament MP.
    Int J Pharm; 2012 Jan 17; 422(1-2):75-82. PubMed ID: 22036653
    [Abstract] [Full Text] [Related]

  • 8. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr 17; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 9. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 10. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr 25; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 11. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.
    Louey MD, Van Oort M, Hickey AJ.
    Pharm Res; 2004 Jul 25; 21(7):1207-13. PubMed ID: 15290861
    [Abstract] [Full Text] [Related]

  • 12. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO, Corrigan OI, Healy AM.
    Int J Pharm; 2006 Sep 28; 322(1-2):22-30. PubMed ID: 16815654
    [Abstract] [Full Text] [Related]

  • 13. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP, Marriott C, Zeng XM.
    Pharm Res; 2007 Feb 28; 24(2):361-9. PubMed ID: 17177114
    [Abstract] [Full Text] [Related]

  • 14. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
    Le VN, Hoang Thi TH, Robins E, Flament MP.
    AAPS PharmSciTech; 2012 Jun 28; 13(2):477-84. PubMed ID: 22399285
    [Abstract] [Full Text] [Related]

  • 15. Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations.
    Shur J, Kubavat HA, Ruecroft G, Hipkiss D, Price R.
    J Pharm Pharmacol; 2012 Sep 28; 64(9):1326-36. PubMed ID: 22881444
    [Abstract] [Full Text] [Related]

  • 16. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C, MacRitchie HB, Zeng XM, Martin GP.
    Int J Pharm; 2006 Dec 01; 326(1-2):39-49. PubMed ID: 16942848
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P, Du J, Smyth HDC.
    J Pharm Sci; 2017 Jan 01; 106(1):366-376. PubMed ID: 27939234
    [Abstract] [Full Text] [Related]

  • 18. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS, Lau R.
    Int J Pharm; 2010 Feb 15; 386(1-2):6-14. PubMed ID: 19922775
    [Abstract] [Full Text] [Related]

  • 19. Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
    Ramachandran V, Murnane D, Hammond RB, Pickering J, Roberts KJ, Soufian M, Forbes B, Jaffari S, Martin GP, Collins E, Pencheva K.
    Mol Pharm; 2015 Jan 05; 12(1):18-33. PubMed ID: 25380027
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.